Physician profile
Jeffrey Mudd
NPI 1518952480
$2,053.25
in general payments reported to CMS, 2019-2025
18 companies · $389 in 2025
The $389 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $169 · 2021: $261 · 2022: $237 · 2023: $324 · 2024: $388 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $530.69 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $480.90 | 2019-2024 | Jornay Pm |
| Corium, LLC | $256.72 | 2021-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $147.89 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $133.74 | 2020-2021 | |
| Glaxosmithkline, LLC. | $93.59 | 2019-2025 | Penmenvy, Bexsero, Pediarix |
| Neurelis, INC. | $76.56 | 2022-2023 | Valtoco |
| Merck Sharp & Dohme LLC | $54.87 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $44.81 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $44.65 | 2024 | Ycanth |
| Biomarin Pharmaceutical INC. | $39.41 | 2022-2024 | Voxzogo 1.2mg |
| Sobi, INC | $30.50 | 2021-2022 | |
| Shire North American Group INC | $28.78 | 2019 | |
| Sanofi Pasteur INC. | $25.48 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.71 | 2025 | Gvoke Hypopen |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Monaghan Medical Corporation | $17.08 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $16.07 | 2024 | Flumist Quadrivalent |
| Tris Pharma INC | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mudd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.